Clinical trial
A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration
NCT01024998 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration
- Lead sponsor
- Genzyme, a Sanofi Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 11, 2010
- Completion date
- July 31, 2018
- Enrollment
- 19 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
age-related maculopathies, age-related maculopathy, eye diseases, gene therapy, macular degeneration, maculopathies, age-related, maculopathy, age-related, retinal degeneration, retinal neovascularization, therapy, gene